デフォルト表紙
市場調査レポート
商品コード
1624037

モルキオ症候群治療薬の市場規模・シェア・成長分析 (治療法別、疾患の種類別、流通チャネル別、地域別):産業予測 (2025~2032年)

Morquio Syndrome Treatment Market Size, Share, Growth Analysis, By Treatment (Enzyme Replacement Therapy, Others), By Disease Type (Morquio A, Morquio B), By Distribution Channel, By Region - Industry Forecast 2025-2032


出版日
発行
SkyQuest
ページ情報
英文 165 Pages
納期
3~5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.06円
モルキオ症候群治療薬の市場規模・シェア・成長分析 (治療法別、疾患の種類別、流通チャネル別、地域別):産業予測 (2025~2032年)
出版日: 2025年01月02日
発行: SkyQuest
ページ情報: 英文 165 Pages
納期: 3~5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のモルキオ症候群治療薬の市場規模は、2023年に1億5,560万米ドルと評価され、2024年の1億6,462万米ドルから2032年には2億5,845万米ドルに成長し、予測期間中 (2025-2032年) にCAGR 5.8%で成長する見通しです。

ムコ多糖症 (MPS IV) に分類されるモルキオ症候群は、主に骨格に影響を及ぼすまれな遺伝性代謝異常症で、グリコサミノグリカンを代謝できない体質を特徴とします。世界のモルキオ症候群治療薬市場は、有病率の上昇、政府や企業による支援の増加、合併症に対処する特殊な薬剤に対する需要の高まりにより、著しい成長を遂げています。メーカー間の戦略的合併や提携は、医療費の増加や技術の進歩に支えられ、また、治療の選択肢を増やすことを目的としています。臨床試験も拡大しており、2022年から2028年にかけて有利な機会をもたらします。しかし、不十分な償還政策や高い製造コストなどの課題は、市場の拡大を阻害する可能性があり、治療選択肢に関する一般市民の意識の低さもこれに拍車をかけています。

目次

イントロダクション

  • 分析目的
  • 市場範囲
  • 定義

分析手法

  • 情報調達
  • 二次・一次データの手法
  • 市場規模予測
  • 市場の想定と制約

エグゼクティブサマリー

  • 市場の概要と展望
  • 需給動向の分析
  • セグメント別の機会分析

市場力学と展望

  • 市場概要
  • 市場規模
  • 市場力学
    • 促進要因と機会
    • 抑制要因と課題
  • ポーター分析

市場の主な考察

  • 主な成功要因
  • 競合の程度
  • 主な投資機会
  • 市場エコシステム
  • 市場魅力度指数 (2024年)
  • PESTEL分析
  • マクロ経済指標
  • バリューチェーン分析
  • 価格分析
  • 技術分析
  • 規制分析
  • 特許分析
  • ケーススタディ

世界のモルキオ症候群治療薬の市場規模・CAGR:治療法別 (2025~2032年)

  • 市場概要
  • 酵素補充療法
  • その他

世界のモルキオ症候群治療薬の市場規模・CAGR:疾患の種類別 (2025~2032年)

  • 市場概要
  • モルキオA
  • モルキオB

世界のモルキオ症候群治療薬の市場規模・CAGR:流通チャネル別 (2025~2032年)

  • 市場概要
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

世界のモルキオ症候群治療薬の市場規模・CAGR (2025~2032年)

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • スペイン
    • フランス
    • 英国
    • イタリア
    • その他欧州地域
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • その他ラテンアメリカ地域
  • 中東・アフリカ
    • GCC諸国
    • 南アフリカ
    • その他中東・アフリカ

競合情勢

  • 上位5社の比較
  • 主要企業の市場ポジショニング (2024年)
  • 主要企業が採用した戦略
  • 市場の近年の動向
  • 主要企業の市場シェア (2024年)
  • 主要企業のプロファイル
    • 企業概要
    • 製品ポートフォリオ分析
    • セグメント別シェア分析
    • 収益の前年比比較 (2022~2024年)

主要企業のプロファイル

  • BioMarin Pharmaceuticals Inc. (米国)
  • Genzyme Corporation (米国)
  • Shire plc (Ireland)
  • JCR Pharmaceuticals Co., Ltd. (日本)
  • Sanofi (フランス)
  • Sangamo Therapeutics (米国)
  • ArmaGen, Inc. (米国)
  • GREEN CROSS CORP (韓国)
  • Concert Pharmaceuticals Inc. (米国)
  • Alexion Pharmaceuticals Inc. (米国)
  • Novo Nordisk A/S (デンマーク)
  • Eli Lilly and Company (米国)
  • Boehringer Ingelheim International GmbH (ドイツ)
  • AstraZeneca (UK)
  • Amgen Inc. (米国)
  • Merck KGaA (ドイツ)
  • Actelion Pharmaceuticals Ltd. (スイス)
  • Biocon (インド)
  • Ultragenyx Pharmaceutical Inc. (米国)
  • Enzyvant Therapeutics Inc. (米国)

結論と推奨事項

目次
Product Code: SQSG35I2026

Global Morquio Syndrome Treatment Market size was valued at USD 155.6 million in 2023 and is poised to grow from USD 164.62 million in 2024 to USD 258.45 million by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

Morquio syndrome, categorized under mucopolysaccharidosis (MPS IV), is a rare inherited metabolic disorder primarily affecting the skeleton, characterized by the body's inability to metabolize glycosaminoglycans. The global treatment market for Morquio syndrome is witnessing significant growth driven by the rising prevalence of the condition, increased governmental and corporate support, and heightened demand for specialized medications addressing its complications. Strategic mergers and partnerships among manufacturers aim to enhance treatment options, supported by rising healthcare expenditure and technological advancements. Clinical trials are also expanding, presenting lucrative opportunities from 2022 to 2028. However, challenges such as inadequate reimbursement policies and high production costs may impede market expansion, compounded by low public awareness regarding treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Morquio Syndrome Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Morquio Syndrome Treatment Market Segmental Analysis

Global Morquio Syndrome Treatment Market is segmented by Treatment, Disease Type, Distribution Channel and region. Based on Treatment, the market is segmented into Enzyme Replacement Therapy and Others. Based on Disease Type, the market is segmented into Morquio A and Morquio B. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Morquio Syndrome Treatment Market

The Morquio Syndrome Treatment market is anticipated to experience significant growth, driven primarily by an upsurge in the number of therapeutic products entering both early and advanced research stages. There is an increasing emphasis on addressing rare diseases, which further fuels market expansion. Numerous pharmaceutical companies are actively developing new medications that, depending on their clinical trial outcomes, are expected to receive regulatory approvals. The recent authorization of elosulfase alfa (VIMIZIM) underscores the potential for additional treatments to reach the market, which is expected to stimulate interest and investment in Morquio Syndrome therapies.

Restraints in the Global Morquio Syndrome Treatment Market

One significant challenge facing the global Morquio Syndrome treatment market is the prohibitive cost associated with treatment options, notably VIMIZIM, which can reach approximately US$ 380,000 per year for patients. This financial burden limits accessibility for many who require these therapies. Furthermore, the market is hindered by a lack of awareness surrounding Morquio Syndrome in developing regions, which contributes to delayed diagnoses and treatments. Additionally, various clinical and regulatory challenges present further obstacles to market growth, complicating the landscape for both patients and healthcare providers seeking effective therapeutic solutions for this rare condition.

Market Trends of the Global Morquio Syndrome Treatment Market

The Global Morquio Syndrome Treatment market is experiencing a notable upward trend, driven by heightened research and development activities from key players and recent regulatory advancements. Pharmaceutical companies, including Ultragenyx Pharmaceutical Inc. and Shire, are actively conducting Phase 3 studies and clinical trials targeting various demographics affected by the syndrome. Moreover, innovative treatments, such as AGT 181 from ArmaGen, are emerging through clinical testing, reflecting a growing commitment to addressing this rare genetic disorder. Increased public awareness and understanding of Morquio syndrome further propel market growth, signaling a promising future for effective treatment options and improving patient outcomes.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Technology Analysis
  • Regulatory Analysis
  • Patent Analysis
  • Case Studies

Global Morquio Syndrome Treatment Market Size by Treatment & CAGR (2025-2032)

  • Market Overview
  • Enzyme Replacement Therapy
  • Others

Global Morquio Syndrome Treatment Market Size by Disease Type & CAGR (2025-2032)

  • Market Overview
  • Morquio A
  • Morquio B

Global Morquio Syndrome Treatment Market Size by Distribution Channel & CAGR (2025-2032)

  • Market Overview
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Global Morquio Syndrome Treatment Market Size & CAGR (2025-2032)

  • North America (Treatment, Disease Type, Distribution Channel)
    • US
    • Canada
  • Europe (Treatment, Disease Type, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Treatment, Disease Type, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Treatment, Disease Type, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Treatment, Disease Type, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • BioMarin Pharmaceuticals Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genzyme Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Shire plc (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • JCR Pharmaceuticals Co., Ltd. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sangamo Therapeutics (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ArmaGen, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GREEN CROSS CORP (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Concert Pharmaceuticals Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Alexion Pharmaceuticals Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novo Nordisk A/S (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boehringer Ingelheim International GmbH (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Actelion Pharmaceuticals Ltd. (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biocon (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ultragenyx Pharmaceutical Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Enzyvant Therapeutics Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations